Celularity (CELU)
(Delayed Data from NSDQ)
$2.65 USD
-0.05 (-1.70%)
Updated Oct 4, 2024 03:57 PM ET
After-Market: $2.68 +0.03 (0.98%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CELU 2.65 -0.05(-1.70%)
Will CELU be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CELU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELU
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
CELU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Other News for CELU
Celularity to Present at H.C. Wainwright?s 26th Annual Global Investment Conference
Celularity Appoints Richard J. Berman to its Board of Directors
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Celularity receives noncompliance notification from Nasdaq
Celularity receives Nasdaq notice regarding late Form 10-Q filing